Cardioembolic Stroke

Circulation Research

Volumn 120, Issue 3, 2017, Pages 514-526

  Kamel, Hooman ^a,b   Healey, Jeff S ^c  

^a FEIL FAMILY BRAIN AND MIND RESEARCH INSTITUTE   (United States)

^b WEILL CORNELL MEDICAL COLLEGE   (United States)

^c MCMASTER UNIVERSITY   (Canada)

Author keywords

anticoagulants; atrial cardiomyopathy; atrial fibrillation; atrial myopathy; embolism; heart failure; stroke

Indexed keywords

ANTICOAGULANT AGENT; ANTITHROMBOCYTIC AGENT; ANTIVITAMIN K;

ACUTE HEART INFARCTION; ANTICOAGULATION; AORTIC ARCH ATHEROMA; ARTICLE; ATHEROMA; ATRIAL FIBRILLATION; BACTERIAL ENDOCARDITIS; CARDIOEMBOLIC STROKE; CARDIOVASCULAR RISK; CEREBROVASCULAR ACCIDENT; CLINICAL EVALUATION; CLINICAL FEATURE; CLINICAL TRIAL (TOPIC); DIAGNOSTIC TEST; HEART ARRHYTHMIA; HEART FAILURE; HEART INFARCTION; HEART VALVE PROSTHESIS; HUMAN; KNOWLEDGE; NEUROIMAGING; PATENT FORAMEN OVALE; PHASE 2 CLINICAL TRIAL (TOPIC); PREVENTIVE MEDICINE; PRIMARY PREVENTION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RISK ASSESSMENT; RISK FACTOR; SYSTOLIC HEART FAILURE; THROMBOGENIC ATRIAL SUBSTRATE; THROMBOGENICITY; HEART DISEASES; HEART SURGERY; MYOCARDIAL INFARCTION; PROCEDURES; STROKE; THROMBOEMBOLISM;

ANTICOAGULANTS; ATRIAL FIBRILLATION; CARDIAC SURGICAL PROCEDURES; CLINICAL TRIALS AS TOPIC; HEART DISEASES; HUMANS; MYOCARDIAL INFARCTION; RISK FACTORS; STROKE; THROMBOEMBOLISM;

EID: 85011851528     PISSN: 00097330     EISSN: 15244571     Source Type: Journal    
DOI: 10.1161/CIRCRESAHA.116.308407     Document Type: Article

References (144)

1. Krishnamurthi RV, Feigin VL, Forouzanfar MH, Mensah GA, Connor M, Bennett DA, Moran AE, Sacco RL, Anderson LM, Truelsen T, O'Donnell M, Venketasubramanian N, Barker-Collo S, Lawes CM, Wang W, Shinohara Y, Witt E, Ezzati M, Naghavi M, Murray C, Global Burden of Diseases IRFS and Group GBDSE. Global and regional burden of frst-ever ischaemic and haemorrhagic stroke during 1990-2010: fnd-ings from the Global Burden of Disease Study 2010. Lancet Glob Health. 2013;1:e259-e281.
2. Adams HP Jr, Bendixen BH, Kappelle LJ, Biller J, Love BB, Gordon DL, Marsh EE III. Classifcation of subtype of acute ischemic stroke. Defnitions for use in a multicenter clinical trial. TOAST. Trial of Org 10172 in Acute Stroke Treatment. Stroke. 1993;24:35-41.
3. Lin HJ, Wolf PA, Kelly-Hayes M, Beiser AS, Kase CS, Benjamin EJ, D'Agostino RB. Stroke severity in atrial fbrillation. The Framingham Study. Stroke. 1996;27:1760-1764.
4. Bogiatzi C, Hackam DG, McLeod AI, Spence JD. Secular trends in isch-emic stroke subtypes and stroke risk factors. Stroke. 2014;45:3208-3213. doi: 10.1161/STROKEAHA.114.006536.
5. Yiin GS, Howard DP, Paul NL, Li L, Luengo-Fernandez R, Bull LM, Welch SJ, Gutnikov SA, Mehta Z, Rothwell PM; Oxford Vascular Study. Age-specifc incidence, outcome, cost, and projected future burden of atrial fbrillation-related embolic vascular events: a popu-lation-based study. Circulation. 2014;130:1236-1244. doi: 10.1161/CIRCULATIONAHA.114.010942.
6. Chugh SS, Havmoeller R, Narayanan K, Singh D, Rienstra M, Benjamin EJ, Gillum RF, Kim YH, McAnulty JH Jr, Zheng ZJ, Forouzanfar MH, Naghavi M, Mensah GA, Ezzati M, Murray CJ. Worldwide epidemiology of atrial fbrillation: a Global Burden of Disease 2010 Study. Circulation. 2014;129:837-847. doi: 10.1161/CIRCULATIONAHA. 113.005119.
7. Aguilar MI, Hart R, Pearce LA. Oral anticoagulants versus antiplatelet therapy for preventing stroke in patients with non-valvular atrial fbril-lation and no history of stroke or transient ischemic attacks. Cochrane Database Syst Rev. 2007:CD006186.
8. Wolf PA, Abbott RD, Kannel WB. Atrial fbrillation as an independent risk factor for stroke: the Framingham Study. Stroke. 1991;22:983-988.
9. Go AS, Hylek EM, Phillips KA, Chang Y, Henault LE, Selby JV, Singer DE. Prevalence of diagnosed atrial fbrillation in adults: national implications for rhythm management and stroke prevention: the AnTicoagulation and Risk Factors in Atrial Fibrillation (ATRIA) Study. JAMA. 2001;285:2370-2375.
10. Ambrosy AP, Fonarow GC, Butler J, Chioncel O, Greene SJ, Vaduganathan M, Nodari S, Lam CS, Sato N, Shah AN, Gheorghiade M. The global health and economic burden of hospitalizations for heart failure: lessons learned from hospitalized heart failure registries. J Am Coll Cardiol. 2014;63:1123-1133. doi: 10.1016/j.jacc.2013.11.053.
11. Chen J, Normand SL, Wang Y, Krumholz HM. National and regional trends in heart failure hospitalization and mortality rates for Medicare benefciaries, 1998-2008. JAMA. 2011;306:1669-1678. doi: 10.1001/jama.2011.1474.
12. Blecker S, Paul M, Taksler G, Ogedegbe G, Katz S. Heart failure-associated hospitalizations in the United States. J Am Coll Cardiol. 2013;61:1259-1267. doi: 10.1016/j.jacc.2012.12.038.
13. Lip GY, Gibbs CR. Does heart failure confer a hypercoagulable state? Virchow's triad revisited. J Am Coll Cardiol. 1999;33:1424-1426.
14. Gottdiener JS, Gay JA, VanVoorhees L, DiBianco R, Fletcher RD. Frequency and embolic potential of left ventricular thrombus in dilated cardiomyopathy: assessment by 2-dimensional echocardiography. Am J Cardiol. 1983;52:1281-1285.
15. Witt BJ, Brown RD Jr, Jacobsen SJ, Weston SA, Ballman K V, Meverden RA, Roger VL. Ischemic stroke after heart failure: a community-based study. Am Heart J. 2006;152:102-109. doi: 10.1016/j.ahj.2005.10.018.
16. Cardiogenic brain embolism. The second report of the Cerebral Embolism Task Force. Arch Neurol. 1989;46:727-743.
17. Koton S, Schneider AL, Rosamond WD, Shahar E, Sang Y, Gottesman RF, Coresh J. Stroke incidence and mortality trends in US communities, 1987 to 2011. JAMA. 2014;312:259-268. doi: 10.1001/jama.2014.7692.
18. Weinreich DJ, Burke JF, Pauletto FJ. Left ventricular mural thrombi complicating acute myocardial infarction. Long-term follow-up with serial echocardiography. Ann Intern Med. 1984;100:789-794.
19. Myint PK, Kwok CS, Roffe C, Kontopantelis E, Zaman A, Berry C, Ludman PF, de Belder MA, Mamas MA; British Cardiovascular Intervention Society and the National Institute for Cardiovascular Outcomes Research. Determinants and outcomes of stroke following percutaneous coronary intervention by indication. Stroke. 2016;47:1500-1507. doi: 10.1161/STROKEAHA.116.012700.
20. Wang Y, Lichtman JH, Dharmarajan K, Masoudi FA, Ross JS, Dodson JA, Chen J, Spertus JA, Chaudhry SI, Nallamothu BK, Krumholz HM. National trends in stroke after acute myocardial infarction among Medicare patients in the United States: 1999 to 2010. Am Heart J. 2015;169:78-85. e74.
21. Hagen PT, Scholz DG, Edwards WD. Incidence and size of patent foramen ovale during the frst 10 decades of life: an autopsy study of 965 normal hearts. Mayo Clin Proc. 1984;59:17-20.
22. Homma S, Sacco RL, Di Tullio MR, Sciacca RR, Mohr JP; PFO in Cryptogenic Stroke Study (PICSS) Investigators. Effect of medical treatment in stroke patients with patent foramen ovale: patent foramen ovale in Cryptogenic Stroke Study. Circulation. 2002;105:2625-2631.
23. Overell JR, Bone I, Lees KR. Interatrial septal abnormalities and stroke: a meta-analysis of case-control studies. Neurology. 2000;55:1172-1179.
24. Handke M, Harloff A, Olschewski M, Hetzel A, Geibel A. Patent fora-men ovale and cryptogenic stroke in older patients. N Engl J Med. 2007;357:2262-2268. doi: 10.1056/NEJMoa071422.
25. Di Tullio MR, Sacco RL, Sciacca RR, Jin Z, Homma S. Patent foramen ovale and the risk of ischemic stroke in a multiethnic population. J Am Coll Cardiol. 2007;49:797-802. doi: 10.1016/j.jacc.2006.08.063.
26. Di Tullio MR, Jin Z, Russo C, Elkind MS, Rundek T, Yoshita M, DeCarli C, Wright CB, Homma S, Sacco RL. Patent foramen ovale, subclinical cerebrovascular disease, and ischemic stroke in a population-based cohort. J Am Coll Cardiol. 2013;62:35-41. doi: 10.1016/j.jacc.2013.03.064.
27. Kent DM, Ruthazer R, Weimar C, et al. An index to identify stroke-relat-ed vs incidental patent foramen ovale in cryptogenic stroke. Neurology. 2013;81:619-625. doi: 10.1212/WNL.0b013e3182a08d59.
28. Kent DM, Dahabreh IJ, Ruthazer R, Furlan AJ, Weimar C, Serena J, Meier B, Mattle HP, Di Angelantonio E, Paciaroni M, Schuchlenz H, Homma S, Lutz JS, Thaler DE. Anticoagulant vs. antiplatelet therapy in patients with cryptogenic stroke and patent foramen ovale: an individual partici-pant data meta-analysis. Eur Heart J. 2015;36:2381-2389. doi: 10.1093/eurheartj/ehv252.
29. Meissner I, Khandheria BK, Sheps SG, Schwartz GL, Wiebers DO, Whisnant JP, Covalt JL, Petterson TM, Christianson TJ, Agmon Y. Atherosclerosis of the aorta: risk factor, risk marker, or innocent by-stander? A prospective population-based transesophageal echocardiog-raphy study. J Am Coll Cardiol. 2004;44:1018-1024. doi: 10.1016/j. jacc.2004.05.075.
30. Amarenco P, Cohen A, Tzourio C, Bertrand B, Hommel M, Besson G, Chauvel C, Touboul PJ, Bousser MG. Atherosclerotic disease of the aortic arch and the risk of ischemic stroke. N Engl J Med. 1994;331:1474-1479. doi: 10.1056/NEJM199412013312202.
31. Di Tullio MR, Sacco RL, Gersony D, Nayak H, Weslow RG, Kargman DE, Homma S. Aortic atheromas and acute ischemic stroke: a trans-esophageal echocardiographic study in an ethnically mixed population. Neurology. 1996;46:1560-1566.
32. Kronzon I, Tunick PA. Aortic atherosclerotic disease and stroke. Circulation. 2006;114:63-75. doi: 10.1161/CIRCULATIONAHA.105.593418.
33. Giruparajah M, Bosch J, Vanassche T, Mattina K, Connolly SJ, Pater C, Hart RG. Global survey of the diagnostic evaluation and management of cryptogenic ischemic stroke. Int J Stroke. 2015;10:1031-1036. doi: 10.1111/ijs.12509.
34. Atherosclerotic disease of the aortic arch as a risk factor for recurrent isch-emic stroke. The French Study of Aortic Plaques in Stroke Group. N Engl J Med. 1996;334:1216-1221.
35. Amarenco P, Davis S, Jones EF, Cohen AA, Heiss WD, Kaste M, Laouénan C, Young D, Macleod M, Donnan GA; Aortic Arch Related Cerebral Hazard Trial Investigators. Clopidogrel plus aspirin versus warfarin in patients with stroke and aortic arch plaques. Stroke. 2014;45:1248-1257. doi: 10.1161/STROKEAHA.113.004251.
36. Nkomo VT, Gardin JM, Skelton TN, Gottdiener JS, Scott CG, Enriquez-Sarano M. Burden of valvular heart diseases: a population-based study. Lancet. 2006;368:1005-1011. doi: 10.1016/S0140-6736(06)69208-8.
37. Nishimura RA, Otto CM, Bonow RO, Carabello BA, Erwin JP III, Guyton RA, O'Gara PT, Ruiz CE, Skubas NJ, Sorajja P, Sundt TM III, Thomas JD; ACC/AHA Task Force Members. 2014 AHA/ACC Guideline for the Management of Patients With Valvular Heart Disease: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation. 2014;129:e521-e643. doi: 10.1161/CIR.0000000000000031.
38. Barreto-Filho JA, Wang Y, Dodson JA, Desai MM, Sugeng L, Geirsson A, Krumholz HM. Trends in aortic valve replacement for elderly patients in the United States, 1999-2011. JAMA. 2013;310:2078-2085. doi: 10.1001/jama.2013.282437.
39. Cannegieter SC, Rosendaal FR, Briët E. Thromboembolic and bleed-ing complications in patients with mechanical heart valve prostheses. Circulation. 1994;89:635-641.
40. Brennan JM, Edwards FH, Zhao Y, O'Brien S, Booth ME, Dokholyan RS, Douglas PS, Peterson ED. Long-term safety and effectiveness of mechanical versus biologic aortic valve prostheses in older patients: results from the Society of Thoracic Surgeons Adult Cardiac Surgery National Database. Circulation. 2013;127:1647-1655.
41. Idrees JJ, Schiltz NK, Johnston DR, Mick S, Smedira NG, Sabik JF III, Blackstone EH, Svensson LG, Soltesz EG. Trends, predictors, and outcomes of stroke after surgical aortic valve replacement in the United States. Ann Thorac Surg. 2016;101:927-935. doi: 10.1016/j.athoracsur.2015.08.024.
42. Kondur A, Briasoulis A, Palla M, Penumetcha A, Mallikethi-Reddy S, Badheka A, Schreiber T. Meta-analysis of transcatheter aortic valve replacement versus surgical aortic valve replacement in patients with severe aortic valve stenosis. Am J Cardiol. 2016;117:252-257. doi: 10.1016/j. amjcard.2015.10.034.
43. Correa de Sa DD, Tleyjeh IM, Anavekar NS, Schultz JC, Thomas JM, Lahr BD, Bachuwar A, Pazdernik M, Steckelberg JM, Wilson WR, Baddour LM. Epidemiological trends of infective endocarditis: a population-based study in Olmsted County, Minnesota. Mayo Clin Proc. 2010;85:422-426.
44. García-Cabrera E, Fernández-Hidalgo N, Almirante B, Ivanova-Georgieva R, Noureddine M, Plata A, Lomas JM, Gálvez-Acebal J, Hidalgo-Tenorio C, Ruíz-Morales J, Martínez-Marcos FJ, Reguera JM, de la Torre-Lima J, de Alarcón González A; Group for the Study of Cardiovascular Infections of the Andalusian Society of Infectious Diseases; Spanish Network for Research in Infectious Diseases. Neurological complications of infective endocarditis: risk factors, outcome, and impact of cardiac surgery: a multicenter observational study. Circulation. 2013;127:2272-2284. doi: 10.1161/CIRCULATIONAHA.112.000813.
45. Dalager-Pedersen M, Søgaard M, Schønheyder HC, Nielsen H, Thomsen RW. Risk for myocardial infarction and stroke after community-acquired bacteremia: a 20-year population-based cohort study. Circulation. 2014;129:1387-1396. doi: 10.1161/CIRCULATIONAHA.113.006699.
46. Merkler AE, Chu SY, Lerario MP, Navi BB, Kamel H. Temporal relationship between infective endocarditis and stroke. Neurology. 2015;85:512-516. doi: 10.1212/WNL.0000000000001835.
47. Hart RG, Diener HC, Coutts SB, Easton JD, Granger CB, O'Donnell MJ, Sacco RL, Connolly SJ; Cryptogenic Stroke/ESUS International Working Group. Embolic strokes of undetermined source: the case for a new clinical construct. Lancet Neurol. 2014;13:429-438. doi: 10.1016/S1474-4422(13)70310-7.
48. Arboix A, Oliveres M, Massons J, Pujades R, Garcia-Eroles L. Early differentiation of cardioembolic from atherothrombotic cerebral infarction: a multivariate analysis. Eur J Neurol. 1999;6:677-683.
49. Ringelstein EB, Koschorke S, Holling A, Thron A, Lambertz H, Minale C. Computed tomographic patterns of proven embolic brain infarctions. Ann Neurol. 1989;26:759-765. doi: 10.1002/ana.410260612.
50. Nah HW, Lee JW, Chung CH, Choo SJ, Kwon SU, Kim JS, Warach S, Kang DW. New brain infarcts on magnetic resonance imaging after coronary artery bypass graft surgery: lesion patterns, mechanism, and predictors. Ann Neurol. 2014;76:347-355. doi: 10.1002/ana.24238.
51. Benavente OR, Hart RG, McClure LA, Szychowski JM, Coffey CS, Pearce LA. Effects of clopidogrel added to aspirin in patients with recent lacunar stroke. N Engl J Med. 2012;367:817-825.
52. Timsit SG, Sacco RL, Mohr JP, Foulkes MA, Tatemichi TK, Wolf PA, Price TR, Hier DB. Early clinical differentiation of cerebral infarction from severe atherosclerotic stenosis and cardioembolism. Stroke. 1992;23:486-491.
53. Ay H, Benner T, Arsava EM, Furie KL, Singhal AB, Jensen MB, Ayata C, Towfghi A, Smith EE, Chong JY, Koroshetz WJ, Sorensen AG. A computerized algorithm for etiologic classifcation of ischemic stroke: the Causative Classifcation of Stroke System. Stroke. 2007;38:2979-2984. doi: 10.1161/STROKEAHA.107.490896.
54. Amarenco P, Bogousslavsky J, Caplan LR, Donnan GA, Wolf ME, Hennerici MG. The ASCOD phenotyping of ischemic stroke (Updated ASCO Phenotyping). Cerebrovasc Dis. 2013;36:1-5. doi: 10.1159/000352050.
55. Marnane M, Duggan CA, Sheehan OC, Merwick A, Hannon N, Curtin D, Harris D, Williams EB, Horgan G, Kyne L, McCormack PM, Duggan J, Moore A, Crispino-O'Connell G, Kelly PJ. Stroke subtype classifcation to mechanism-specifc and undetermined categories by TOAST, A-S-C-O, and causative classifcation system: direct comparison in the North Dublin population stroke study. Stroke. 2010;41:1579-1586. doi: 10.1161/STROKEAHA.109.575373.
56. Adams HP Jr, Kassell NF, Torner JC, Sahs AL. CT and clinical correlations in recent aneurysmal subarachnoid hemorrhage: a preliminary report of the Cooperative Aneurysm Study. Neurology. 1983;33:981-988.
57. Freilinger TM, Schindler A, Schmidt C, Grimm J, Cyran C, Schwarz F, Bamberg F, Linn J, Reiser M, Yuan C, Nikolaou K, Dichgans M, Saam T. Prevalence of nonstenosing, complicated atherosclerotic plaques in cryptogenic stroke. JACC Cardiovasc Imaging. 2012;5:397-405. doi: 10.1016/j.jcmg.2012.01.012.
58. Gupta G, Gialdini G, Giambrone A, Lerario M, Baradaran H, Navi B, Marshall R, Iadecola C, Kamel H. Association between non-stenosing carotid artery plaque on magnetic resonance angiography and acute ischemic stroke. JACC Cardiovasc Imaging. 2016;9:1228-1229.
59. Sacco RL, Ellenberg JH, Mohr JP, Tatemichi TK, Hier DB, Price TR, Wolf PA. Infarcts of undetermined cause: the NINCDS Stroke Data Bank. Ann Neurol. 1989;25:382-390. doi: 10.1002/ana.410250410.
60. Gladstone DJ, Spring M, Dorian P, et al; EMBRACE Investigators and Coordinators. Atrial fbrillation in patients with cryptogenic stroke. N Engl J Med. 2014;370:2467-2477. doi: 10.1056/NEJMoa1311376.
61. Sanna T, Diener HC, Passman RS, Di Lazzaro V, Bernstein RA, Morillo CA, Rymer MM, Thijs V, Rogers T, Beckers F, Lindborg K, Brachmann J; CRYSTAL AF Investigators. Cryptogenic stroke and underlying atrial fbrillation. N Engl J Med. 2014;370:2478-2486. doi: 10.1056/NEJMoa1313600.
62. Kamel H, Okin PM, Elkind MS, Iadecola C. Atrial fbrillation and mechanisms of stroke: time for a new model. Stroke. 2016;47:895-900. doi: 10.1161/STROKEAHA.115.012004.
63. Wolf PA, Dawber TR, Thomas HE Jr, Kannel WB. Epidemiologic as-sessment of chronic atrial fbrillation and risk of stroke: the Framingham study. Neurology. 1978;28:973-977.
64. Connolly SJ, Ezekowitz MD, Yusuf S, et al; RE-LY Steering Committee and Investigators. Dabigatran versus warfarin in patients with atri-al fbrillation. N Engl J Med. 2009;361:1139-1151. doi: 10.1056/NEJMoa0905561.
65. Healey JS, Connolly SJ, Gold MR, Israel CW, Van Gelder IC, Capucci A, Lau CP, Fain E, Yang S, Bailleul C, Morillo CA, Carlson M, Themeles E, Kaufman ES, Hohnloser SH; ASSERT Investigators. Subclinical atrial fbrillation and the risk of stroke. N Engl J Med. 2012;366:120-129. doi: 10.1056/NEJMoa1105575.
66. Epstein AE, Alexander JC, Gutterman DD, Maisel W, Wharton JM; American College of Chest Physicians. Anticoagulation: American College of Chest Physicians guidelines for the prevention and management of postoperative atrial fbrillation after cardiac surgery. Chest. 2005;128:24S-27S.
67. January CT, Wann LS, Alpert JS, et al; ACC/AHA Task Force Members. 2014 AHA/ACC/HRS guideline for the management of patients with atrial fbrillation: a report of the American College of Cardiology/American Heart Association Task Force on practice guidelines and the Heart Rhythm Society. Circulation. 2014;130:e199-e267. doi: 10.1161/CIR.0000000000000041.
68. Walkey AJ, Hammill BG, Curtis LH, Benjamin EJ. Long-term outcomes following development of new-onset atrial fbrillation during sepsis. Chest. 2014;146:1187-1195. doi: 10.1378/chest.14-0003.
69. Gialdini G, Nearing K, Bhave PD, Bonuccelli U, Iadecola C, Healey JS, Kamel H. Perioperative atrial fbrillation and the long-term risk of isch-emic stroke. JAMA. 2014;312:616-622. doi: 10.1001/jama.2014.9143.
70. Lubitz SA, Yin X, Rienstra M, Schnabel RB, Walkey AJ, Magnani JW, Rahman F, McManus DD, Tadros TM, Levy D, Vasan RS, Larson MG, Ellinor PT, Benjamin EJ. Long-term outcomes of secondary atrial f-brillation in the community: the Framingham Heart Study. Circulation. 2015;131:1648-1655. doi: 10.1161/CIRCULATIONAHA.114.014058.
71. Levine SA, Harvey EA. A study of uninfected mural thrombi of the heart. Am J Med Sci. 1930;180:365-371.
72. Larsen BS, Kumarathurai P, Falkenberg J, Nielsen OW, Sajadieh A. Excessive atrial ectopy and short atrial runs increase the risk of stroke beyond incident atrial fbrillation. J Am Coll Cardiol. 2015;66:232-241. doi: 10.1016/j.jacc.2015.05.018.
73. Brambatti M, Connolly SJ, Gold MR, et al; ASSERT Investigators. Temporal relationship between subclinical atrial fbrillation and embolic events. Circulation. 2014;129:2094-2099. doi: 10.1161/CIRCULATIONAHA.113.007825.
74. Dewland TA, Vittinghoff E, Mandyam MC, Heckbert SR, Siscovick DS, Stein PK, Psaty BM, Sotoodehnia N, Gottdiener JS, Marcus GM. Atrial ectopy as a predictor of incident atrial fbrillation: a cohort study. Ann Intern Med. 2013;159:721-728. doi: 10.7326/0003-4819-159-11-201312030-00004.
75. Engström G, Hedblad B, Juul-Möller S, Tydén P, Janzon L. Cardiac arrhythmias and stroke: increased risk in men with high frequency of atrial ectopic beats. Stroke. 2000;31:2925-2929.
76. Binici Z, Intzilakis T, Nielsen OW, Køber L, Sajadieh A. Excessive supraventricular ectopic activity and increased risk of atrial fbril-lation and stroke. Circulation. 2010;121:1904-1911. doi: 10.1161/CIRCULATIONAHA.109.874982.
77. Orejarena LA, Vidaillet H Jr, DeStefano F, Nordstrom DL, Vierkant RA, Smith PN, Hayes JJ. Paroxysmal supraventricular tachycardia in the general population. J Am Coll Cardiol. 1998;31:150-157.
78. Andrade J, Khairy P, Dobrev D, Nattel S. The clinical profle and patho-physiology of atrial fbrillation: relationships among clinical features, epidemiology, and mechanisms. Circ Res. 2014;114:1453-1468. doi: 10.1161/CIRCRESAHA.114.303211.
79. Elkind MS. Infammatory mechanisms of stroke. Stroke. 2010;41:S3-S8. doi: 10.1161/STROKEAHA.110.594945.
80. Blackshear JL, Pearce LA, Hart RG, Zabalgoitia M, Labovitz A, Asinger RW, Halperin JL. Aortic plaque in atrial fbrillation: prevalence, predictors, and thromboembolic implications. Stroke. 1999;30:834-840.
81. Zabalgoitia M, Halperin JL, Pearce LA, Blackshear JL, Asinger RW, Hart RG. Transesophageal echocardiographic correlates of clinical risk of thromboembolism in nonvalvular atrial fbrillation. Stroke Prevention in Atrial Fibrillation III Investigators. J Am Coll Cardiol. 1998;31:1622-1626.
82. Manolio TA, Kronmal RA, Burke GL, O'Leary DH, Price TR. Short-term predictors of incident stroke in older adults. The Cardiovascular Health Study. Stroke. 1996;27:1479-1486.
83. Lodder J, Bamford JM, Sandercock PA, Jones LN, Warlow CP. Are hypertension or cardiac embolism likely causes of lacunar infarction? Stroke. 1990;21:375-381.
84. Boiten J, Lodder J. Lacunar infarcts. Pathogenesis and validity of the clinical syndromes. Stroke. 1991;22:1374-1378.
85. Cai H, Li Z, Goette A, Mera F, Honeycutt C, Feterik K, Wilcox JN, Dudley SC Jr, Harrison DG, Langberg JJ. Downregulation of endocardial nitric oxide synthase expression and nitric oxide production in atrial fbrilla-tion: potential mechanisms for atrial thrombosis and stroke. Circulation. 2002;106:2854-2858.
86. Frustaci A, Chimenti C, Bellocci F, Morgante E, Russo MA, Maseri A. Histological substrate of atrial biopsies in patients with lone atrial fbrilla-tion. Circulation. 1997;96:1180-1184.
87. Mihm MJ, Yu F, Carnes CA, Reiser PJ, McCarthy PM, Van Wagoner DR, Bauer JA. Impaired myofbrillar energetics and oxidative injury during human atrial fbrillation. Circulation. 2001;104:174-180.
88. Vaziri SM, Larson MG, Benjamin EJ, Levy D. Echocardiographic pre-dictors of nonrheumatic atrial fbrillation. The Framingham Heart Study. Circulation. 1994;89:724-730.
89. Warraich HJ, Gandhavadi M, Manning WJ. Mechanical discordance of the left atrium and appendage: a novel mechanism of stroke in paroxysmal atrial fbrillation. Stroke. 2014;45:1481-1484. doi: 10.1161/STROKEAHA.114.004800.
90. Alpert MA, Munuswamy K. Electrocardiographic diagnosis of left atrial enlargement. Arch Intern Med. 1989;149:1161-1165.
91. Goyal SB, Spodick DH. Electromechanical dysfunction of the left atrium associated with interatrial block. Am Heart J. 2001;142:823-827. doi: 10.1067/mhj.2001.118110.
92. Scott CC, Leier CV, Kilman JW, Vasko JS, Unverferth DV. The effect of left atrial histology and dimension on P wave morphology. J Electrocardiol. 1983;16:363-366.
93. Kamel H, Soliman EZ, Heckbert SR, Kronmal RA, Longstreth WT Jr, Nazarian S, Okin PM. P-wave morphology and the risk of incident ischemic stroke in the Multi-Ethnic Study of Atherosclerosis. Stroke. 2014;45:2786-2788. doi: 10.1161/STROKEAHA.114.006364.
94. Kamel H, Hunter M, Moon YP, Yaghi S, Cheung K, Di Tullio MR, Okin PM, Sacco RL, Soliman EZ, Elkind MS. Electrocardiographic left atrial abnormality and risk of stroke: Northern Manhattan Study. Stroke. 2015;46:3208-3212. doi: 10.1161/STROKEAHA.115.009989.
95. Kamel H, O'Neal WT, Okin PM, Loehr LR, Alonso A, Soliman EZ. Electrocardiographic left atrial abnormality and stroke subtype in the atherosclerosis risk in communities study. Ann Neurol. 2015;78:670-678. doi: 10.1002/ana.24482.
96. Karas MG, Devereux RB, Wiebers DO, Whisnant JP, Best LG, Lee ET, Howard BV, Roman MJ, Umans JG, Kizer JR. Incremental value of biochemical and echocardiographic measures in prediction of ischemic stroke: the Strong Heart Study. Stroke. 2012;43:720-726. doi: 10.1161/STROKEAHA.111.631168.
97. Barnes ME, Miyasaka Y, Seward JB, Gersh BJ, Rosales AG, Bailey KR, Petty GW, Wiebers DO, Tsang TS. Left atrial volume in the prediction of frst ischemic stroke in an elderly cohort without atrial fbrillation. Mayo Clin Proc. 2004;79:1008-1014. doi: 10.4065/79.8.1008.
98. Di Tullio MR, Sacco RL, Sciacca RR, Homma S. Left atrial size and the risk of ischemic stroke in an ethnically mixed population. Stroke. 1999;30:2019-2024.
99. Benjamin EJ, D'Agostino RB, Belanger AJ, Wolf PA, Levy D. Left atri-al size and the risk of stroke and death. The Framingham Heart Study. Circulation. 1995;92:835-841.
100. Cioff G, Cramariuc D, Dalsgaard M, Davidsen ES, Egstrup K, Rossebø AB, de Simone G, Gerdts E. Left atrial systolic force and outcome in asymptomatic mild to moderate aortic stenosis. Echocardiography. 2012;29:1038-1044. doi: 10.1111/j.1540-8175.2012.01744.x.
101. Yaghi S, Moon YP, Mora-McLaughlin C, Willey JZ, Cheung K, Di Tullio MR, Homma S, Kamel H, Sacco RL, Elkind MS. Left atrial enlargement and stroke recurrence: the Northern Manhattan Stroke Study. Stroke. 2015;46:1488-1493. doi: 10.1161/STROKEAHA. 115.008711.
102. Turakhia MP, Ziegler PD, Schmitt SK, Chang Y, Fan J, Than CT, Keung EK, Singer DE. Atrial fbrillation burden and short-term risk of stroke: case-crossover analysis of continuously recorded heart rhythm from cardiac electronic implanted devices. Circ Arrhythm Electrophysiol. 2015;8:1040-1047. doi: 10.1161/CIRCEP.114.003057.
103. Glotzer TV, Daoud EG, Wyse DG, Singer DE, Ezekowitz MD, Hilker C, Miller C, Qi D, Ziegler PD. The relationship between daily atrial tachyar-rhythmia burden from implantable device diagnostics and stroke risk: the TRENDS study. Circ Arrhythm Electrophysiol. 2009;2:474-480. doi: 10.1161/CIRCEP.109.849638.
104. Al-Khatib SM, Thomas L, Wallentin L, Lopes RD, Gersh B, Garcia D, Ezekowitz J, Alings M, Yang H, Alexander JH, Flaker G, Hanna M, Granger CB. Outcomes of apixaban vs. warfarin by type and duration of atrial fbrillation: results from the ARISTOTLE trial. Eur Heart J. 2013;34:2464-2471. doi: 10.1093/eurheartj/eht135.
105. Vanassche T, Lauw MN, Eikelboom JW, Healey JS, Hart RG, Alings M, Avezum A, Díaz R, Hohnloser SH, Lewis BS, Shestakovska O, Wang J, Connolly SJ. Risk of ischaemic stroke according to pattern of atrial fbrillation: analysis of 6563 aspirin-treated patients in ACTIVE-A and AVERROES. Eur Heart J. 2015;36:281-27a. doi: 10.1093/eurheartj/ehu307.
106. Chao TF, Liu CJ, Chen SJ, Wang KL, Lin YJ, Chang SL, Lo LW, Hu YF, Tuan TC, Wu TJ, Chen TJ, Tsao HM, Chen SA. Atrial fbrillation and the risk of ischemic stroke: does it still matter in patients with a CHA2DS2-VASc score of 0 or 1? Stroke. 2012;43:2551-2555. doi: 10.1161/STROKEAHA.112.667865.
107. Ruff CT, Giugliano RP, Braunwald E, Hoffman EB, Deenadayalu N, Ezekowitz MD, Camm AJ, Weitz JI, Lewis BS, Parkhomenko A, Yamashita T, Antman EM. Comparison of the effcacy and safety of new oral anticoagulants with warfarin in patients with atrial fbrillation: a meta-analysis of randomised trials. Lancet. 2014;383:955-962. doi: 10.1016/S0140-6736(13)62343-0.
108. Connolly SJ, Eikelboom J, Joyner C, et al; AVERROES Steering Committee and Investigators. Apixaban in patients with atri-al fbrillation. N Engl J Med. 2011;364:806-817. doi: 10.1056/NEJMoa1007432.
109. Pollack CV Jr, Reilly PA, Eikelboom J, et al. Idarucizumab for dabi-gatran reversal. N Engl J Med. 2015;373:511-520. doi: 10.1056/NEJMoa1502000.
110. Siegal DM, Curnutte JT, Connolly SJ, Lu G, Conley PB, Wiens BL, Mathur VS, Castillo J, Bronson MD, Leeds JM, Mar FA, Gold A, Crowther MA. Andexanet Alfa for the reversal of factor Xa inhibitor activity. N Engl J Med. 2015;373:2413-2424. doi: 10.1056/NEJMoa1510991.
111. Shah SV, Gage BF. Cost-effectiveness of dabigatran for stroke prophylaxis in atrial fbrillation. Circulation. 2011;123:2562-2570. doi: 10.1161/CIRCULATIONAHA.110.985655.
112. Kamel H, Easton JD, Johnston SC, Kim AS. Cost-effectiveness of apix-aban vs warfarin for secondary stroke prevention in atrial fbrillation. Neurology. 2012;79:1428-1434. doi: 10.1212/WNL.0b013e31826d5fe8.
113. Lip GY, Skjøth F, Rasmussen LH, Larsen TB. Oral anticoagulation, aspirin, or no therapy in patients with nonvalvular AF with 0 or 1 stroke risk factor based on the CHA2DS2-VASc score. J Am Coll Cardiol. 2015;65:1385-1394. doi: 10.1016/j.jacc.2015.01.044.
114. Friberg L, Skeppholm M, Terént A. Beneft of anticoagulation unlikely in patients with atrial fbrillation and a CHA2DS2-VASc score of 1. J Am Coll Cardiol. 2015;65:225-232. doi: 10.1016/j.jacc.2014.10.052.
115. Longstreth WT Jr, Kronmal RA, Thompson JL, Christenson RH, Levine SR, Gross R, Brey RL, Buchsbaum R, Elkind MS, Tirschwell DL, Seliger SL, Mohr JP, deFilippi CR. Amino terminal pro-B-type natriuretic pep-tide, secondary stroke prevention, and choice of antithrombotic therapy. Stroke. 2013;44:714-719. doi: 10.1161/STROKEAHA.112.675942.
116. Diener HC, Easton JD, Granger CB, Cronin L, Duffy C, Cotton D, Brueckmann M, Sacco RL; RE-SPECT ESUS Investigators. Design of Randomized, double-blind, Evaluation in secondary Stroke Prevention comparing the EffcaCy and safety of the oral Thrombin inhibitor dabi-gatran etexilate vs. acetylsalicylic acid in patients with Embolic Stroke of Undetermined Source (RE-SPECT ESUS). Int J Stroke. 2015;10:1309-1312. doi: 10.1111/ijs.12630.
117. Stoddard MF, Dawkins PR, Prince CR, Ammash NM. Left atrial appendage thrombus is not uncommon in patients with acute atrial fbrillation and a recent embolic event: a transesophageal echocardiographic study. J Am Coll Cardiol. 1995;25:452-459.
118. Holmes DR, Reddy VY, Turi ZG, Doshi SK, Sievert H, Buchbinder M, Mullin CM, Sick P; PROTECT AF Investigators. Percutaneous closure of the left atrial appendage versus warfarin therapy for prevention of stroke in patients with atrial fbrillation: a randomised non-inferiority trial. Lancet. 2009;374:534-542. doi: 10.1016/S0140-6736(09)61343-X.
119. Reddy VY, Sievert H, Halperin J, Doshi SK, Buchbinder M, Neuzil P, Huber K, Whisenant B, Kar S, Swarup V, Gordon N, Holmes D; PROTECT AF Steering Committee and Investigators. Percutaneous left atrial appendage closure vs warfarin for atrial fbrillation: a randomized clinical trial. JAMA. 2014;312:1988-1998. doi: 10.1001/jama.2014.15192.
120. Camm AJ, Lip GY, De Caterina R, Savelieva I, Atar D, Hohnloser SH, Hindricks G, Kirchhof P; ESC Committee for Practice Guidelines (CPG). 2012 focused update of the ESC Guidelines for the management of atrial fbrillation: an update of the 2010 ESC Guidelines for the man-agement of atrial fbrillation. Developed with the special contribution of the European Heart Rhythm Association. Eur Heart J. 2012;33:2719-2747. doi: 10.1093/eurheartj/ehs253.
121. Meschia JF, Bushnell C, Boden-Albala B, et al; American Heart Association Stroke Council; Council on Cardiovascular and Stroke Nursing; Council on Clinical Cardiology; Council on Functional Genomics and Translational Biology; Council on Hypertension. Guidelines for the primary prevention of stroke: a statement for healthcare professionals from the American Heart Association/American Stroke Association. Stroke. 2014;45:3754-3832. doi: 10.1161/STR.0000000000000046.
122. Verma A, Cairns JA, Mitchell LB, Macle L, Stiell IG, Gladstone D, McMurtry MS, Connolly S, Cox JL, Dorian P, Ivers N, Leblanc K, Nattel S, Healey JS; CCS Atrial Fibrillation Guidelines Committee. 2014 focused update of the Canadian Cardiovascular Society Guidelines for the management of atrial fbrillation. Can J Cardiol. 2014;30:1114-1130. doi: 10.1016/j.cjca.2014.08.001.
123. Calkins H, Kuck KH, Cappato R, et al; Heart Rhythm Society Task Force on Catheter and Surgical Ablation of Atrial Fibrillation. 2012 HRS/EHRA/ECAS expert consensus statement on catheter and surgical ablation of atrial fbrillation: recommendations for patient se-lection, procedural techniques, patient management and follow-up, defnitions, endpoints, and research trial design: a report of the Heart Rhythm Society (HRS) Task Force on Catheter and Surgical Ablation of Atrial Fibrillation. Developed in partnership with the European Heart Rhythm Association (EHRA), a registered branch of the European Society of Cardiology (ESC) and the European Cardiac Arrhythmia Society (ECAS); and in collaboration with the American College of Cardiology (ACC), American Heart Association (AHA), the Asia Pacifc Heart Rhythm Society (APHRS), and the Society of Thoracic Surgeons (STS). Endorsed by the governing bodies of the American College of Cardiology Foundation, the American Heart Association, the European Cardiac Arrhythmia Society, the European Heart Rhythm Association, the Society of Thoracic Surgeons, the Asia Pacifc Heart Rhythm Society, and the Heart Rhythm Society. Heart Rhythm. 2012;9:632-696.e21. doi: 10.1016/j.hrthm.2011.12.016.
124. Al-Khatib SM, Allen LaPointe NM, Chatterjee R, Crowley MJ, Dupre ME, Kong DF, Lopes RD, Povsic TJ, Raju SS, Shah B, Kosinski AS, McBroom AJ, Sanders GD. Rate-and rhythm-control therapies in pa-tients with atrial fbrillation: a systematic review. Ann Intern Med. 2014;160:760-773. doi: 10.7326/M13-1467.
125. Wynn GJ, Das M, Bonnett LJ, Panikker S, Wong T, Gupta D. Effcacy of catheter ablation for persistent atrial fbrillation: a systematic review and meta-analysis of evidence from randomized and nonrandomized controlled trials. Circ Arrhythm Electrophysiol. 2014;7:841-852. doi: 10.1161/CIRCEP.114.001759.
126. Wyse DG, Waldo AL, DiMarco JP, Domanski MJ, Rosenberg Y, Schron EB, Kellen JC, Greene HL, Mickel MC, Dalquist JE, Corley SD; Atrial Fibrillation Follow-up Investigation of Rhythm Management (AFFIRM) Investigators. A comparison of rate control and rhythm control in pa-tients with atrial fbrillation. N Engl J Med. 2002;347:1825-1833. doi: 10.1056/NEJMoa021328.
127. Pathak RK, Middeldorp ME, Lau DH, Mehta AB, Mahajan R, Twomey D, Alasady M, Hanley L, Antic NA, McEvoy RD, Kalman JM, Abhayaratna WP, Sanders P. Aggressive risk factor reduction study for atrial fbril-lation and implications for the outcome of ablation: the ARREST-AF cohort study. J Am Coll Cardiol. 2014;64:2222-2231. doi: 10.1016/j. jacc.2014.09.028.
128. Homma S, Thompson JL, Pullicino PM, et al; WARCEF Investigators. Warfarin and aspirin in patients with heart failure and sinus rhythm. N Engl J Med. 2012;366:1859-1869. doi: 10.1056/NEJMoa1202299.
129. Cleland JG, Findlay I, Jafri S, Sutton G, Falk R, Bulpitt C, Prentice C, Ford I, Trainer A, Poole-Wilson PA. The Warfarin/Aspirin Study in Heart failure (WASH): a randomized trial comparing antithrombotic strategies for patients with heart failure. Am Heart J. 2004;148:157-164. doi: 10.1016/j.ahj.2004.03.010.
130. Massie BM, Collins JF, Ammon SE, Armstrong PW, Cleland JG, Ezekowitz M, Jafri SM, Krol WF, O'Connor CM, Schulman KA, Teo K, Warren SR; WATCH Trial Investigators. Randomized trial of warfarin, aspirin, and clopidogrel in patients with chronic heart failure: the Warfarin and Antiplatelet Therapy in Chronic Heart Failure (WATCH) trial. Circulation. 2009;119:1616-1624. doi: 10.1161/CIRCULATIONAHA.108.801753.
131. Pullicino PM, Qian M, Sacco RL, et al; WARCEF Investigators. Recurrent stroke in the warfarin versus aspirin in reduced cardiac ejection fraction (WARCEF) trial. Cerebrovasc Dis. 2014;38:176-181. doi: 10.1159/000365502.
132. Eikelboom JW, Connolly SJ, Brueckmann M, et al; RE-ALIGN Investigators. Dabigatran versus warfarin in patients with mechanical heart valves. N Engl J Med. 2013;369:1206-1214. doi: 10.1056/NEJMoa1300615.
133. O'Gara PT, Kushner FG, Ascheim DD, et al; American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. 2013 ACCF/AHA guideline for the management of ST-elevation myocardial infarction: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation. 2013;127:e362-e425. doi: 10.1161/CIR.0b013e3182742cf6.
134. Weinsaft JW, Kim RJ, Ross M, Krauser D, Manoushagian S, LaBounty TM, Cham MD, Min JK, Healy K, Wang Y, Parker M, Roman MJ, Devereux RB. Contrast-enhanced anatomic imaging as compared to contrast-enhanced tissue characterization for detection of left ventricular thrombus. JACC Cardiovasc Imaging. 2009;2:969-979. doi: 10.1016/j. jcmg.2009.03.017.
135. Weinsaft JW, Kim J, Medicherla CB, Ma CL, Codella NC, Kukar N, Alaref S, Kim RJ, Devereux RB. Echocardiographic algorithm for post-myocardial infarction lv thrombus: a gatekeeper for thrombus evaluation by delayed enhancement CMR. JACC Cardiovasc Imaging. 2016;9:505-515. doi: 10.1016/j.jcmg.2015.06.017.
136. Molina CA, Selim MH. Anticoagulation in patients with stroke with infective endocarditis: the sword of Damocles. Stroke. 2011;42:1799-1800. doi: 10.1161/STROKEAHA.111.622423.
137. Emberson J, Lees KR, Lyden P, et al; Stroke Thrombolysis Trialists' Collaborative Group. Effect of treatment delay, age, and stroke severity on the effects of intravenous thrombolysis with alteplase for acute ischaemic stroke: a meta-analysis of individual patient data from randomised trials. Lancet. 2014;384:1929-1935. doi: 10.1016/S0140-6736(14)60584-5.
138. Xian Y, Liang L, Smith EE, Schwamm LH, Reeves MJ, Olson DM, Hernandez AF, Fonarow GC, Peterson ED. Risks of intracranial hemorrhage among patients with acute ischemic stroke receiving warfarin and treated with intravenous tissue plasminogen activator. JAMA. 2012;307:2600-2608.
139. Demaerschalk BM, Kleindorfer DO, Adeoye OM, Demchuk AM, Fugate JE, Grotta JC, Khalessi AA, Levy EI, Palesch YY, Prabhakaran S, Saposnik G, Saver JL, Smith EE; American Heart Association Stroke Council and Council on Epidemiology and Prevention. Scientifc rationale for the inclusion and exclusion criteria for intravenous alteplase in acute ischemic stroke: a statement for healthcare professionals from the American Heart Association/American Stroke Association. Stroke. 2016;47:581-641. doi: 10.1161/STR.0000000000000086.
140. Manoukian SV, Feit F, Mehran R, Voeltz MD, Ebrahimi R, Hamon M, Dangas GD, Lincoff AM, White HD, Moses JW, King SB III, Ohman EM, Stone GW. Impact of major bleeding on 30-day mortality and clinical outcomes in patients with acute coronary syndromes: an analysis from the ACUITY Trial. J Am Coll Cardiol. 2007;49:1362-1368. doi: 10.1016/j.jacc.2007.02.027.
141. Kamel H, Johnston SC, Kirkham JC, Turner CG, Kizer JR, Devereux RB, Iadecola C. Association between major perioperative hemorrhage and stroke or Q-wave myocardial infarction. Circulation. 2012;126:207-212. doi: 10.1161/CIRCULATIONAHA.112.094326.
142. Goyal M, Menon BK, van Zwam WH, et al; HERMES collaborators. Endovascular thrombectomy after large-vessel ischaemic stroke: a meta-analysis of individual patient data from fve randomised trials. Lancet. 2016;387:1723-1731. doi: 10.1016/S0140-6736(16)00163-X.
143. Whiteley WN, Slot KB, Fernandes P, Sandercock P, Wardlaw J. Risk factors for intracranial hemorrhage in acute ischemic stroke patients treated with recombinant tissue plasminogen activator: a systematic review and meta-analysis of 55 studies. Stroke. 2012;43:2904-2909. doi: 10.1161/STROKEAHA.112.665331.
144. Feigin VL, Forouzanfar MH, Krishnamurthi R, et al; Global Burden of Diseases, Injuries, and Risk Factors Study 2010 (GBD 2010) and the GBD Stroke Experts Group. Global and regional burden of stroke during 1990-2010: fndings from the Global Burden of Disease Study 2010. Lancet. 2014;383:245-254.